
Outline of Adopted Projects
This adopted project will work to develop a treatment for pediatric patients with congenital heart disease by conducting a validation study (Phase III clinical study) of JRM-001*2 in collaboration with Okayama University (Head Office: Okayama City, Okayama Prefecture), a national university corporation, which is a collaborating institution.
As a result of this selection, Methuselah may receive up to 1 billion yen in consignment fees for a period of up to five years.
JRM-001 is subject to the Ministry of Health, Labour and Welfare's Pioneer Review Designation System*3 and is intended to be launched as a breakthrough treatment for serious rare diseases in children, for which practical application is required as soon as possible. Through this selected project, Methuselah will promote a validation study (Phase III clinical study) of JRM-001 to confirm its efficacy and safety.
About JRM-001
The target disease, monoventricular disease, and its challenges
Single ventricle syndrome is a rare congenital heart disease in which the heart has only one main ventricle to pump blood, and it is a rare disease that occurs in about 310 to 810 patients per year*4. The long-term prognosis of this disease is not good, with a 20-year survival rate of about 69%*5.
Although the repeated surgical repair surgeries from childhood and the impact on daily life and employment as patients grow up reduce their QOL*6, there are no drugs or regenerative medical products on the market to date that are indicated for the improvement of cardiac function.
Treatment Concept

JRM-001 is a regenerative medicine product for rare diseases*7 that mainly consists of cardiac stem cells (CSCs).
Patients with univentricular disease undergo surgical repair as standard treatment, and the small amount of surplus cardiac tissue obtained during this procedure is used as raw material for regenerative medical products. The cells are then transported to a cell processing facility where they are cultured and formulated before being administered to the individual's body again at a medical institution (Figure).
As an autologous regenerative medicine that uses your own surplus cells, JRM-001 is characterized by low additional burden to the body and low risk of immune rejection.
Background of Development
("Japan Regenerative Medicine")*8 in April 2022, Methuselah has continued to develop regenerative medicine products for rare diseases (JRM-001) using autologous intracardiac stem cells that the company has been developing.
Research results suggesting the safety and efficacy of a treatment using intracardiac stem cells for monoventricular heart disease have been reported in Phase I[ix] and Phase II clinical studies[x] conducted by Okayama University as a human stem cell clinical study. Based on the results of these clinical studies, Methuselah had previously conducted a validation study (Phase III clinical study).
Comments from the development team
Professor, Department of Cardiovascular Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Dr. Shingo Kasahara, Chief, Division of Cardiovascular Surgery, Chief, Division of Pediatric Cardiovascular Surgery, Chief, Division of Cardiovascular Disease Intensive Care Unit
The challenge adopted this time is to develop a treatment for congenital heart disease called monoventricular heart disease using regenerative medicine. The prognosis of patients with univentricular disease has improved with the development of various surgical methods. However, some patients with univentricular disease show a loss of heart muscle function that is unique to univentricular disease, and severe heart failure is a major problem. This severe heart failure can also cause a chain reaction of dysfunction in multiple organs throughout the body.
Through two clinical studies conducted to date, Okayama University has confirmed the long-term efficacy of intracardiac stem cells. With this adoption, we hope to complete the validation study together with Methuselah and bring this innovative treatment to patients as soon as possible.
Vice President, Business Development Department, Methuselah Corporation
Kotaro Toda, Head of Development, JRM-001, Japan Regenerative Medicine Division
(Founding member of Japan Regenerative Medicine Co.)
Since 2013, when Japan Regenerative Medicine was founded, we have consistently worked on the practical application of this technology with a strong sense of mission to deliver new therapeutic products to the children who will lead the future. At present, as we approach the final stage of development, we have succeeded in resolving various technical issues in a short period of time through collaboration with Methuselah.
We are strongly convinced that the practical application of this technology will bring hope to patients with univentricular disease who have limited treatment options, and the adoption of this project is a major step toward realizing this goal.
Outline of Adopted Projects
Title of Research and Development: Development of a treatment for pediatric patients with congenital heart disease using intracardiac stem cells
Representative organization: Methuselah Corporation, Subcontracting organization: Okayama University
3. R&D period and total contract amount: up to 5 years, maximum 1 billion yen
4. reference information:https://www.amed.go.jp/koubo/17/01/1701C_00002.html
About Methuselah
Methuselah is a clinical development stage startup founded in 2016 to provide new fibroblast and stem cell-based therapies for chronic diseases that do not respond well to existing treatments.
By integrating drug discovery research, process development, and dosage optimization, we aim to provide innovative therapies.
As a major pipeline product, we started Phase I investigator-initiated clinical trials for a regenerative medicine product for heart failure (MTC001), which combines autologous cardiac-derived fibroblasts and a catheter for administration. In addition, we are conducting Phase III clinical trials for a regenerative medicine product for pediatric congenital heart disease (JRM-001) using autologous cardiac stem cells, which has been approved under the Pioneer Review Designation System and designated as a regenerative medicine product for rare diseases.
| name of company | Methuselah Corporation |
| Establishment | 2016 |
| Location | Life Innovation Center, 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, Japan |
| representative | Takahiro Iwamiya, Kenichi Nogami |
| uniform resouce locator | https://www.metcela.com/ |
Supplemental Explanation
*1 The "Creation of Innovative Infrastructure for Clinical Research and Development (CiCLE)" is an AMED project that aims to support the creation of innovative pharmaceuticals and medical devices through industry-academia-government collaboration and accelerate their practical application. Among these, the "start-up type (ViCLE)" is aimed at supporting venture companies.
*2 A regenerative medicine product under development by Methuselah. Aiming to improve long-term prognosis by improving cardiac function through administration to patients with single ventricle disease, a rare pediatric disease for which no curative treatment exists.
3A system that designates drugs, etc. that have been developed ahead of the rest of the world and are expected to be remarkably effective at an early stage of treatment and aims for early commercialization through various types of support, in order to achieve early commercialization of innovative drugs, medical devices, and regenerative medicine products in Japan.
4 Estimated by the Company based on "Explanation of Diseases" (https://www.nanbyou.or.jp/entry/4369), Japan Intractable Disease Information Center.
*5Information Center for Intractable Diseases, "Overview, Diagnostic Criteria, etc." (https://www.nanbyou.or.jp/entry/4370)
6 Quality of life: A concept meaning quality of life.
7Designated by the Minister of Health, Labour and Welfare based on Article 77-2 of the Pharmaceuticals and Medical Devices Act, after hearing the opinions of the Pharmaceutical Affairs and Food Sanitation Council, as those that meet conditions such as the number of target patients in Japan is less than 50,000 and the need for the product is particularly high in terms of medical care.
*8 related press releases:https://www.metcela.com/2022/04/04/acquisition_j/
9 Ishigami et al. Circ Res. 2015 Feb 13;116(4):653-664
10 Ishigami et al. Circ Res. 2017 Mar 31;120(7):1162-1173, Sano et al. Circ Res. 2018 Mar 30;122(7):994-1005









